论文部分内容阅读
目的对比化疗配合放射治疗与单纯放疗治疗宫颈癌疗效,探讨综合治疗中晚期宫颈癌的疗效及安全性。方法 64例Ⅱ~Ⅲ中晚期宫颈癌患者分成两组,放疗同步化疗(A组)34例,在放疗同时给予PF方案化疗2~4周期,化疗第一天开始行放射治疗。单纯放疗组(B组)30例,两组放射治疗均用6MV X射线盆腔大野前后对穿体外照射,DT:45~50Gy;并加192IrHDR腔内后装照射,A点DT:20~25Gy。结果 A组和B组近期有效率分别为100%和96.67%,两组的差异无统计学意义(P>0.05)。A组和B组的3年生存率分别为73.51%和56.67%,差异有统计学意义(P<0.05)。毒性反应方面,同步放化疗组高于单纯放疗组,尤以造血系统和消化道反应为主,但大部分能耐受。结论中晚期宫颈癌患者PF方案同步放化疗可提高生存率。
Objective To compare the efficacy of radiotherapy with radiotherapy and radiotherapy alone in the treatment of cervical cancer, and to explore the efficacy and safety of comprehensive treatment of advanced cervical cancer. Methods Sixty-four patients with stage Ⅱ-Ⅲ advanced cervical cancer were divided into two groups. Radiotherapy was performed on the first day after chemotherapy in 34 patients with concurrent chemotherapy of radiotherapy (group A) and 2 to 4 cycles of radiotherapy with PF regimen. Thirty patients in the radiotherapy group (group B) received radiotherapy alone before and after 6MV X-ray pelvic surgery, with DT: 45-50 Gy; and 192IrHDR intracavitary post-irradiation, A point DT: 20-25 Gy. Results The recent effective rates in group A and group B were 100% and 96.67%, respectively, with no significant difference between the two groups (P> 0.05). The 3-year survival rates of group A and group B were 73.51% and 56.67%, respectively, with significant difference (P <0.05). Toxicity, concurrent chemoradiotherapy group than radiotherapy alone group, especially in the hematopoietic system and gastrointestinal reactions, but most can tolerate. Conclusion Concurrent chemoradiotherapy with PF regimen in patients with advanced cervical cancer can improve the survival rate.